Clinical Trial Update: Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic study of alglucosidase alfa in Pompe disease patients has completed and results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Alglucosidase alfa (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease, Glycogen Storage Disease Type II (GSD II) | Phase 4 | Status: COMPLETED | Results posted: 2021-06-11